Hoth Therapeutics, Inc. (HOTH)
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
$6.97M
Mr. Robb Knie
4.00
New York, NY
Feb 15, 2019
-0.65
$-1.55
14.18
14.62
-12,533.35%
-0.99
-0.00
0.79
124.07
14.62
-74.38%
-81.79%
Similar stocks (13)
NeuroBo Pharmaceuticals, Inc.
NRBO
Kiora Pharmaceuticals, Inc.
KPRX
Cardio Diagnostics Holdings, Inc.
CDIO
Sonnet BioTherapeutics Holdings, Inc.
SONN
Avenue Therapeutics, Inc.
ATXI
Allarity Therapeutics, Inc.
ALLR
Phio Pharmaceuticals Corp.
PHIO
Kiromic BioPharma, Inc.
KRBP
Quoin Pharmaceuticals, Ltd.
QNRX
180 Life Sciences Corp.
ATNF
Aditxt, Inc.
ADTX
Revelation Biosciences, Inc.
REVB
TRACON Pharmaceuticals, Inc.
TCON
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (13)
NeuroBo Pharmaceuticals, Inc.
NRBO
Kiora Pharmaceuticals, Inc.
KPRX
Cardio Diagnostics Holdings, Inc.
CDIO
Sonnet BioTherapeutics Holdings, Inc.
SONN
Avenue Therapeutics, Inc.
ATXI
Allarity Therapeutics, Inc.
ALLR
Phio Pharmaceuticals Corp.
PHIO
Kiromic BioPharma, Inc.
KRBP
Quoin Pharmaceuticals, Ltd.
QNRX
180 Life Sciences Corp.
ATNF
Aditxt, Inc.
ADTX
Revelation Biosciences, Inc.
REVB
TRACON Pharmaceuticals, Inc.
TCON
ETF Exposure (2)
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Extended Market Index Fund
VXF
0%